BrainsWay Ltd. (TLV:BWAY)
2,531.00
+31.00 (1.24%)
Nov 20, 2025, 5:25 PM IDT
BrainsWay Revenue
BrainsWay had revenue of $13.51M USD in the quarter ending September 30, 2025, with 28.66% growth. This brings the company's revenue in the last twelve months to $49.09M, up 27.08% year-over-year. In the year 2024, BrainsWay had annual revenue of $41.02M with 29.04% growth.
Revenue (ttm)
$49.09M
Revenue Growth
+27.08%
P/S Ratio
5.83
Revenue / Employee
$409.12K
Employees
120
Market Cap
947.91M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.02M | 9.23M | 29.04% |
| Dec 31, 2023 | 31.79M | 4.61M | 16.96% |
| Dec 31, 2022 | 27.18M | -2.48M | -8.36% |
| Dec 31, 2021 | 29.66M | 7.60M | 34.46% |
| Dec 31, 2020 | 22.06M | -1.04M | -4.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 55.55B |
| Danel (Adir Yeoshua) | 2.84B |
| Novolog (Pharm-Up 1966) | 2.04B |
| Ilex Medical | 927.57M |
| Kamada | 578.74M |
| SofWave Medical | 255.13M |
| InterCure | 243.12M |
| Bait Bakfar | 106.25M |
BrainsWay News
- 6 days ago - BrainsWay (BWAY) Kicks Off Clinical Trial for Alcohol Use Disorder Treatment - GuruFocus
- 6 days ago - BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder - GlobeNewsWire
- 10 days ago - BrainsWay: High Growth Set To Persist - Seeking Alpha
- 10 days ago - BrainsWay (BWAY) Receives Updated "Buy" Rating from Analysts | BWAY Stock News - GuruFocus
- 10 days ago - BrainsWay (BWAY) Gains FDA Nod for Expanded Use of Deep TMS in Adolescents - GuruFocus
- 10 days ago - BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21 - GlobeNewsWire
- 12 days ago - BrainsWay Ltd (BWAY) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... - GuruFocus
- 12 days ago - Q3 2025 Brainsway Ltd Earnings Call Transcript - GuruFocus